Category

Commentary

Hope For Alzheimer’s Disease

By | Commentary, Presentations

Alzheimer’s disease results from the progressive death of brain cells or neurons. Over time the loss of neurons affects processing of information leading to increasingly severe memory loss, disorientation, mood and behavior changes. Are we making any progress on finding a cure for Alzheimer’s disease? Yes, because we now know…

Read More

Not All Amyloid-beta Therapeutics Are Created Equal: Promis Neurosciences Lead Product Candidate For Alzheimer’s Disease Shows Improved Therapeutic Potency Versus Other Amyloid Beta-directed Antibodies

By | Commentary, Presentations

NOT ALL AMYLOID-BETA THERAPEUTICS ARE CREATED EQUAL: PROMIS NEUROSCIENCES LEAD PRODUCT CANDIDATE FOR ALZHEIMER’S DISEASE SHOWS IMPROVED THERAPEUTIC POTENCY VERSUS OTHER AMYLOID BETA-DIRECTED ANTIBODIES Download PDF Humanized PMN310 Shows Significantly Greater Binding to the Toxic Oligomer Fraction from Alzheimer’s Disease Brain Extract Compared to Aducanumab Low molecular weight toxic Aβ…

Read More

AAIC White Paper July 19 2017

By | Commentary

STATE OF THE ART AT AAIC 2017 This year’s Alzheimer’s Association International Conference (AAIC) is the largest yet with 5,600 experts from around the world representing medical institutions, academia and industry. It is striking that the field now appears to have reached a consensus on the central role of toxic…

Read More

Critical Insight: Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease

By | Commentary

Critical Insight:  Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease Refinement of the Amyloid beta cascade hypothesis – Prions vs. Plaque The presence of Amyloid beta (Aβ) plaque is a hallmark of Alzheimer’s disease (AD) and several clinical trials have been undertaken to reduce or…

Read More